Table 2. Characteristics of patients treated by neoadjuvant chemotherapy in the overall population (n=451), and in the population evaluated for NPI (n=163), BGI (n=228), MNPI (n=153) and MBGI (n=222).
|
Population evaluated for |
|||||
|---|---|---|---|---|---|
| Characteristics | Overall | NPI | BGI | MNPI | MBGI |
| Median age (years) | 49.0 | 50.0 | 49.0 | 51.0 | 50.0 |
| Characteristics at diagnosis | Number of patients (%) | ||||
| Menopausal status | |||||
| Premenopausal | 247 (54.8) | 83 (50.9) | 119 (52.2) | 76 (49.7) | 114 (51.3) |
| Menopausal | 204 (45.2) | 80 (49.1) | 109 (47.8) | 77 (50.3) | 108 (48.7) |
| Stage | |||||
| II | 338 (74.9) | 118 (72.4) | 177 (77.6) | 107 (69.9) | 170 (76.6) |
| III | 113 (25.1) | 45 (27.6) | 51 (22.4) | 46 (30.1) | 52 (23.4) |
| Pathology | |||||
| Invasive ductal | 359 (79.6) | 142 (87.1) | 198 (86.8) | 125 (81.6) | 181 (81.5) |
| Invasive lobular | 55 (12.2) | 4 (2.5) | 6 (2.6) | 14 (9.2) | 20 (9.0) |
| Others | 37 (8.2) | 17 (10.4) | 24 (10.6) | 14 (9.2) | 21 (9.5) |
| SBR grading | |||||
| I | 46 (14.7) | 22 (17.2) | 40 (22.0) | 18 (15.4) | 36 (21.2) |
| II | 156 (49.8) | 69 (53.9) | 94 (51.7) | 65 (55.5) | 91 (53.5) |
| III | 111 (35.5) | 37 (28.9) | 48 (26.3) | 34 (29.1) | 43 (25.3) |
| MSBR grading | |||||
| 1 | 9 (3.0) | 5 (4.6) | 7 (4.4) | 5 (4.2) | 8 (4.6) |
| 2 | 71 (23.9) | 23 (20.9) | 43 (26.9) | 31 (25.6) | 53 (30.1) |
| 3 | 98 (33.0) | 43 (39.1) | 59 (36.9) | 46 (38.0) | 65 (36.9) |
| 4 | 72 (24.3) | 28 (25.4) | 34 (21.2) | 27 (22.3) | 33 (18.7) |
| 5 | 47 (15.8) | 11 (10.0) | 17 (10.6) | 12 (9.9) | 17 (9.7) |
| Surgery | n=396 | n=163 | n=228 | n=153 | n=222 |
| Conservative | 280 (70.7) | 101 (62.0) | 159 (69.7) | 99 (64.7) | 158 (71.2) |
| MRM | 116 (29.3) | 62 (38.0) | 69 (30.3) | 54 (35.3) | 64 (28.8) |
| Characteristics after treatment | |||||
| Residual tumour size (cm) (range) | 1.5 | 2.0 | 2.0 | 2.0 | 2.0 |
| (0.0–8.0) | (0.0–8.0) | (0.0–8.0) | (0.0–8.0) | (0.0–8.0) | |
| Axillary lymph node | |||||
| 0 | 128 (46.2) | 57 (35.0) | 55 (36.0) | ||
| 1–3 | 91 (32.9) | 65 (39.9) | 58 (37.9) | ||
| ⩾4 | 58 (20.9) | 41 (25.1) | 40 (26.1) | ||
| SBR grade | |||||
| I | 62 (26.3) | 37 (22.7) | 61 (26.7) | 27 (19.9) | 51 (25.6) |
| II | 123 (52.1) | 88 (54.0) | 119 (52.2) | 78 (57.3) | 109 (54.8) |
| III | 51 (21.6) | 38 (23.3) | 48 (21.1) | 31 (22.8) | 39 (19.6) |
| MSBR grading | |||||
| 1 | 12 (5.3) | 5 (4.6) | 7 (4.4) | 5 (4.2) | 8 (4.6) |
| 2 | 67 (29.5) | 23 (20.9) | 43 (26.9) | 31 (25.6) | 53 (30.1) |
| 3 | 74 (32.6) | 43 (39.1) | 59 (36.9) | 46 (38.0) | 65 (36.9) |
| 4 | 49 (21.6) | 28 (25.4) | 34 (21.2) | 27 (22.3) | 33 (18.7) |
| 5 | 25 (11.0) | 11 (10.0) | 17 (10.6) | 12 (9.9) | 17 (9.7) |
| Adjuvant treatment | n=442 | n=161 | n=226 | n=151 | n=220 |
| Radiotherapy | 422 (95.7) | 156 (97.0) | 219 (96.9) | 147 (97.4) | 214 (97.3) |
| Chemotherapy | 100 (24.5) | 42 (28.0) | 58 (27.1) | 39 (25.8) | 57 (25.9) |
| Hormonotherapy | 200 (46.3) | 80 (51.3) | 108 (49.3) | 87 (57.6) | 116 (52.7) |
SBR=Scarff–Bloom–Richardson grading in patients with invasive ductal carcinoma; MSBR=modified SBR grading; MRM=modified radical mastectomy. In each group, the number of patients is not always equal to the total population due to the presence of certain nonmeasurable characteristics, withdrawal for drug allergies or toxicities. Moreover, 55 patients had not undergone surgery: 42 AVCF/M treated by radiotherapy alone, three acute allergies to taxotere, six progressions, two surgery refusals after clinical complete response, two too early.